RecruitingNCT05670938

Follow-up After Surgery for Testicular Cancer

Follow-up After Surgery for Testicular Cancer: the Prospective, Single Centre FUTURE-testis Implementation Study


Sponsor

Erasmus Medical Center

Enrollment

145 participants

Start Date

Nov 30, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study follows men who have had surgery for early-stage testicular cancer to compare different follow-up strategies (e.g., how often to do scans and check-ups). The goal is to find the most effective and least burdensome surveillance approach that still catches any cancer recurrence early. **You may be eligible if...** - You are 18 or older - You have been diagnosed with early-stage testicular cancer (no distant spread) confirmed by tissue analysis - You were treated with curative intent (surgery) less than 3 months ago - Your post-surgery scans and tumor marker blood tests show no signs of remaining cancer **You may NOT be eligible if...** - Your cancer has already spread to distant organs - Your tumor markers remain elevated after surgery - You still have visible cancer on post-operative scans - You are not able to commit to the follow-up schedule Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05670938


Related Trials